tradingkey.logo

Elutia Inc

ELUT
View Detailed Chart
0.987USD
+0.045+4.73%
Close 02/06, 16:00ETQuotes delayed by 15 min
42.00MMarket Cap
LossP/E TTM

Elutia Inc

0.987
+0.045+4.73%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.73%

5 Days

-5.99%

1 Month

+57.18%

6 Months

-49.89%

Year to Date

+42.50%

1 Year

-62.32%

View Detailed Chart

TradingKey Stock Score of Elutia Inc

Currency: USD Updated: 2026-02-06

Key Insights

Elutia Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 82 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elutia Inc's Score

Industry at a Glance

Industry Ranking
82 / 159
Overall Ranking
211 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Elutia Inc Highlights

StrengthsRisks
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.38M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.38M.
Fairly Valued
The company’s latest PE is -1.58, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 61.99K shares of this stock.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
3.500
Target Price
+271.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Elutia Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Elutia Inc Info

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Ticker SymbolELUT
CompanyElutia Inc
CEOMills (C. Randal)
Websitehttps://elutia.com/
KeyAI